---
document_datetime: 2023-09-21 21:47:51
document_pages: 27
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/novorapid-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: novorapid-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 45.6479973
conversion_datetime: 2025-12-23 20:42:41.256971
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## NovoRapid

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| N/0146               | Minor change in labelling or package leaflet not connected with theSPC(Art.61.3 Notification)                                             | 20/03/2023                          |                                            | PL                              |           |
| WS/2351              | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. | 09/02/2023                          | n/a                                        |                                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedfor all otherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics,annex II, labelling,package leaflet).The CD is issued within twomonths of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation(EU) No.712/2012, or within one yearfor other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation                                                                                                                                                                                                                                                                                                                                                     |            |     |                                |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| WS/2302/G          | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.I.a.4.e -Change to in-process tests orlimits appliedduring themanufactureof theAS-Deletion of an in-process testwhichmayhave a significant effectontheoverallqualityoftheAS B.I.a.4.e -Change to in-process tests or limits applied during the manufacture of the AS - Deletion of anin-process test whichmayhave a significant | 15/12/2022 | n/a |                                |
| IB/0143            | B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change in themanufacturingprocess                                                                                                                                                                                                                                                                                                                                                     | 10/11/2022 | n/a |                                |
| PSUSA/1749/ 202109 | PeriodicSafetyUpdateEUSingleassessment- insulin aspart                                                                                                                                                                                                                                                                                                                                                                                                                               | 05/05/2022 | n/a | PRACRecommendation-maintenance |
| WS/2056            | Thiswas an applicationfor avariationfollowing a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.II.c.3.a.2-Change in source of an excipient or                                                                                                                                                                                                                                                                                               | 10/06/2021 | n/a |                                |

<div style=\"page-break-after: always\"></div>

|                    | reagent with TSE risk - From TSE risk material to vegetable or synthetic origin-For excipients or reagentsUSEDinthemanufactureofabiol/immunol ASorinabiol/immunolmedicinalproduct                                                                                                                            |            |            |                                  |                                |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------|
| PSUSA/1749/ 202009 | PeriodicSafetyUpdateEUSingle assessment- insulin aspart                                                                                                                                                                                                                                                      | 06/05/2021 | n/a        |                                  | PRACRecommendation-maintenance |
| WS/1997            | This was an application for a variation following a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. B.II.g.2-Introduction of apost approval change management protocol related to the finished product                                                                      | 11/03/2021 | n/a        |                                  |                                |
| IB/0137/G          | Thiswasanapplicationforagroupofvariations. B.II.g.5.c-Implementation ofchangesforeseen in anapproved changemanagementprotocol-Fora biological/immunological medicinalproduct B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess | 04/11/2020 | n/a        |                                  |                                |
| WS/1901            | This was an application for a variationfollowing a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                               | 24/09/2020 | 22/09/2021 | SmPC, Annex II, Labelling and PL |                                |

<div style=\"page-break-after: always\"></div>

| PSUSA/1749/ 201909   | PeriodicSafetyUpdateEUSingle assessment- insulin aspart                                                                                                                                                                                                          | 17/04/2020   | n/a   | PRACRecommendation-maintenance   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------------------|
| IG/1184              | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                        | 07/02/2020   | n/a   |                                  |
| IG/1172              | A.7-Administrativechange-Deletion of manufacturing sites                                                                                                                                                                                                         | 16/01/2020   | n/a   |                                  |
| WS/1687              | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation | 05/12/2019   | n/a   |                                  |
| IG/1167              | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                          | 22/11/2019   | n/a   |                                  |
| IG/1149              | B.II.b.1.a-Replacement or addition of a manufacturing sitefortheFp-Secondarypackaging site                                                                                                                                                                       | 04/10/2019   | n/a   |                                  |
| 11/0128              | B.II.g.2-Introduction of a post approvalchange managementprotocolrelatedto thefinishedproduct                                                                                                                                                                    | 18/07/2019   | n/a   |                                  |
| IG/1092              | B.IV.1.a.1-Change of a measuring or administration device-Addition orreplacement of a devicewhich is notanintegratedpartof theprimarypackaging- Device with CE marking                                                                                           | 12/07/2019   | n/a   |                                  |

<div style=\"page-break-after: always\"></div>

| PSUSA/1749/ 201809   | PeriodicSafetyUpdateEUSingle assessment- insulin aspart                                                                                                                                                                                                                                                                                    | 26/04/2019   | 01/07/2019   |           | Based on thepost-marketingdatasubmittedwithin this PSUR,thePRACconcludes that anaphylacticreactions should be added to section 4.8 of the SmPC for Fiasp, in line with the SmPC for NovoRapid and NovoMix. Following 7newreportedcasesofmedicallyconfirmedsystemic allergic reactions for Fiasp and the already established evidence suggesting a causal relationship between insulin aspart and anaphylactic reactions, the updates to the section4.8ofSmPCforFiasparejustified.   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0127            | C.I.11.a -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wording agreedbythecompetentauthority                                                                                                                                                           | 10/05/2019   | n/a          |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| WS/1564              | Thiswas an applicationfor a variationfollowing a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changesto a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate | 04/04/2019   | n/a          |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/1066              | A.7-Administrative change-Deletion of manufacturingsites                                                                                                                                                                                                                                                                                   | 29/03/2019   | n/a          |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| N/0123               | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                        | 05/12/2018   | 28/03/2019   | Labelling |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/1405   | Thiswas an applicationfor avariationfollowing a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. B.I.e.5.c-Implementation of changesforeseen in an approved change management protocol-For a biological/immunological medicinalproduct                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 19/07/2018   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0121   | Updateofsection4.2oftheSmPC toinclude a passivediscouragementofwithdrawinginsulinwith a syringe from cartridges and pre-filled pens; update ofsection6.6oftheSmPCnottoallowthe withdrawal of insulinwithasyringefrom cartridges and pre-filled pens in emergency situations. This variationwassubmitted tofulfil a recommendation bythePRACinNovember2017,subsequenttothe evaluationofthesignal onpotential increasedriskof medicationerrorassociatedwithwithdrawinginsulin frompre-filledpens and cartridges,leading to dysglycaemia.The PL is updated accordingly. In addition, the MAH took the opportunity to reinsert andclarifyinformation in theSmPCregarding mixing ofNovoRapidwithNPH insulin(sections4.2and 6.2),whichhaspreviouslybeendeletedfromthe SmPCbymistake.Othereditorialchangesarealso proposed within this variation. Moreover, Annex A is updated toreflectthatonlythevial istobeused intravenously. C.I.z-Changes(Safety/Efficacy)ofHuman and | 26/04/2018   | 28/03/2019 | SmPC, Labelling and PL | NovoRapid(from areusablepen) isonly suitablefor subcutaneous injections.If administrationby syringe or intravenous injection is necessary,a vial should beused.If administrationbyinfusionpump is necessary,avial or NovoRapidPumpCartshould be used. NovoRapid can onlybe mixedwith NPH(Neutral Protamine Hagedorn) insulin in a syringe for subcutaneous use.When NovoRapid is mixedwith NPH insulin,NovoRapid should be drawn into the syringefirst,and themixture should be injected immediately after mixing. Insulin mixtures should notbeadministeredintravenouslyorusedwitha subcutaneous insulin infusion pump. |

<div style=\"page-break-after: always\"></div>

| PSUSA/1749/        |                                                                                                                                                                                                                          |                       | n/a        |                        |                                                                                                                                                                                                                                             |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 201709 IG/0859     | PeriodicSafetyUpdateEUSingle assessment- insulin aspart A.5.b-Administrative change-Change in the name                                                                                                                   | 12/04/2018 01/12/2017 | n/a        |                        | PRACRecommendation-maintenance                                                                                                                                                                                                              |
| 11/0118            | B.II.f.1.c-Stability of FP-Change in storage conditionsforbiological medicinal products,when the stability studieshave notbeenperformed in accordancewithan approvedstabilityprotocol                                    | 22/06/2017            | 18/09/2017 | SmPC, Labelling and PL | Duringuse orwhencarried asa spare,NovoRapid FlexPen/NovoRapidFlexTouchshouldbestoredbelow 30°C. Alternatively, they can be stored in a refrigerator (2°C - 8°C). Do not freeze. Keep the pen cap on the pen in order to protect from light. |
| WS/1132            | This was an applicationfor a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.e.2-Introduction of a post approval change managementprotocolrelatedtotheAS | 05/05/2017            | n/a        |                        |                                                                                                                                                                                                                                             |
| PSUSA/1749/ 201609 | PeriodicSafetyUpdateEUSingleassessment- insulin aspart                                                                                                                                                                   | 05/05/2017            | n/a        |                        | PRACRecommendation-maintenance                                                                                                                                                                                                              |
| 11/0115            | B.II.d.1.e-Change in the specificationparameters and/or limits of the finished product - Change outsidetheapprovedspecificationslimitsrange                                                                              | 26/01/2017            | n/a        |                        |                                                                                                                                                                                                                                             |
| 1I/0112            | ExtensionofIndication toincludetheuseof NovoRapidinchildrenfrom1to2yearsofagefor thetreatmentofdiabetesmellitus;asa                                                                                                      | 15/09/2016            | 21/10/2016 | SmPC, Labelling and    | Please refer to the published Assessment Report Novorapid H/C/000258/I1/0112                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | consequence, sections 4.1,4.2,4.4 and 5.1 of the SmPC are updated.ThePackage Leaflet is updated in accordance.Furthermore,the PI is brought in line with thelatestQRDtemplateversion10. C.I.6.a -Change(s) to therapeutic indication(s) - Additionof anewtherapeuticindicationor modificationofanapprovedone   |            |            | PL                               |                                                                                                                                                                                                 |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0114 | Updateof sections 4.4 and4.8oftheSmPCwith additional informationregarding avoidance of accidental mix-ups and medication errors. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical, clinical orpharmacovigilance data                                                                | 13/10/2016 | 18/09/2017 | SmPC                             | Avoidance of accidental mix-ups/medication errors: Patientsmustbeinstructedtoalwayschecktheinsulin labelbeforeeachinjectionto avoidaccidentalmix-ups betweenNovoRapid and otherinsulinproducts. |
| N/0113  | UpdateofAnnexIIIAforNovorapidPumpcart packsize25(5x5)cartridges(multipack)following a change in thepackage design of themultipack. Minor changeinlabelling orpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                       | 01/08/2016 | 21/10/2016 | Labelling                        |                                                                                                                                                                                                 |
| 11/0111 | Updateof sections4.2and4.4oftheSmPC to add the useof theYpsoPumpinsulinpumpfor the NovoRapidPumpCartpresentation.ThePackage Leaflet andLabelling are updated accordingly.The RMPwasupdated(Edition2,version 1)to reflect the use of the YpsoPump insulin pump. In addition, the Marketing authorisation holder | 23/06/2016 | 21/10/2016 | SmPC, Annex II, Labelling and PL | Theproductinformationfor NovoRapid hasbeen updated to allowforuse of the NovoRapidPumpcartpresentation with the YpsoPump system, a pump system suitable for insulin infusion.                   |

<div style=\"page-break-after: always\"></div>

|                    | (MAH)took theopportunity tobring the product information in line withtheQRDtemplateversion9.1 andtoimplementminorcorrectionsthroughout. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality,preclinical,clinical orpharmacovigilance data   |            |            |                 |                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------|
| PSUSA/1749/ 201509 | PeriodicSafetyUpdateEUSingleassessment- insulin aspart                                                                                                                                                                                                   | 14/04/2016 | n/a        |                 | PRACRecommendation-maintenance |
| 11/0107            | B.II.d.1.e-Change in the specification parameters and/or limits of the finished product-Change outside the approved specifications limits range                                                                                                          | 28/01/2016 | n/a        |                 |                                |
| IG/0642            | A.5.a -Administrative change -Change in the name and/or address of a manufacturer/importer responsibleforbatchrelease                                                                                                                                    | 21/12/2015 | 25/01/2016 | Annex II and PL |                                |
| IG/0644            | A.5.b -Administrative change -Change in the name and/oraddressofamanufacturer/importerofthe finishedproduct,includingqualitycontrolsites (excludingmanufacturerforbatchrelease)                                                                          | 10/12/2015 | n/a        |                 |                                |
| IG/0594            | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                  | 04/09/2015 | n/a        |                 |                                |
| IB/0105            | B.II.h.z - Adventitious Agents Safety - Other variation                                                                                                                                                                                                  | 04/09/2015 | n/a        |                 |                                |
| IB/0104            | B.II.b.2.a-Change to importer,batch release                                                                                                                                                                                                              | 23/06/2015 | n/a        |                 |                                |

<div style=\"page-break-after: always\"></div>

|                    | arrangements and quality control testing of the FP - Replacement/additionofasitewherebatch control/testing takesplace                                                                                                                                    |            |            |                        |                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------|
| PSUSA/1749/ 201409 | PeriodicSafetyUpdateEUSingleassessment- insulin aspart                                                                                                                                                                                                   | 07/05/2015 | n/a        |                        | PRACRecommendation-maintenance |
| IB/0102            | B.II.e.5.a.2-Change in pack size of the finished product - Change in the number of units (e.g. tablets，ampoules,etc.）inapack-Changeoutside therangeofthecurrentlyapprovedpacksizes                                                                       | 16/01/2015 | 25/01/2016 | SmPC, Labelling and PL |                                |
| WS/0428            | This was an application for a variation following a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. tointroducechangestotheactivesubstance manufacturingprocess B.I.a.z-Change in manufacture of the AS-Other variation | 22/05/2014 | n/a        |                        |                                |
| IA/0101            | B.II.b.3.a-Changeinthemanufacturingprocessof thefinishedorintermediateproduct-Minorchange inthemanufacturingprocess                                                                                                                                      | 14/04/2014 | n/a        |                        |                                |
| WS/0437            | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.b.2.e -Change in testprocedure forAS or                                                                    | 23/01/2014 | n/a        |                        |                                |

<div style=\"page-break-after: always\"></div>

|         | startingmaterial/reagent/intermediate-Other changes to a testprocedure(including replacement or addition) for the AS or a starting                                                                                                                                                                                                                                              |            |            |                        | material/intermediate     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------|
|         | B.II.e.1.b.2 - Change in immediate packaging of the finishedproduct-Type of container-Sterile medicinalproductsandbiological/immunological                                                                                                                                                                                                                                      | 21/11/2013 | 10/01/2014 | SmPC, Labelling and PL | I1/0092 medicinalproducts |
| N/0096  | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                             | 30/07/2013 | 10/01/2014 | PL                     |                           |
| IA/0098 | A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                                                                                          | 26/07/2013 | n/a        |                        |                           |
|         | This was an application for a group of variations. B.II.b.1.c-Replacement or addition of a manufacturingsitefortheFp-Sitewhere any manufacturing operation(s)takeplace,exceptbatch release,batchcontrol,andsecondarypackaging,for biological/immunological medicinal products. B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 25/07/2013 | n/a        |                        | 11/0097/G                 |
| IG/0280 | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                           | 17/04/2013 | n/a        |                        |                           |
|         | B.II.b.1.a-Replacement or addition of a                                                                                                                                                                                                                                                                                                                                         | 18/01/2013 | n/a        |                        | IAIN/0094                 |

<div style=\"page-break-after: always\"></div>

|           | manufacturingsitefortheFp-Secondarypackaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0251   | B.II.e.5.b - Change in pack size of the finished product-Deletion of a pack size(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/01/2013 | 10/01/2014 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 11/0091   | Update of sections 4.2 and 4.8 of the SmPC in order modify the wording regarding lipodystrophy; and updateofsections4.6and4.8of theSmPCtoreflect theSmPC guideline.ThePackage Leaflet is updated accordingly. Furthermore,the PI is being brought in line with the latestQRDtemplateversion8.0rev.1. TheMAH has alsotaken the opportunity to implementtheresultsfromthereadabilitytest bridging report TheMAHhasalsomadeeditorial changes throughout the text to allign it with thePI of Levemir and NovoMix. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdue inparticular tonewquality,pre- clinical,clinical orpharmacovigilance data | 21/06/2012 | 31/07/2012 | SmPC,Annex II, Labelling and PL  | The information about the risk of developing lipodystrophy includinginformation onhowtoreduce thisriskhasbeen clarifiedthroughouttheproductinformation.Thishasbeen done tomaketheinformationmorelegibleforboth healthcare professionals andpatients,and specifically to highlightthatrotatingtheinjectionsitedoesnot necessarilypreventdevelopmentoflipodystrophybutmay help to reduce the risk for such development. Changestoallannexeshavebeenintroducedinorderto comply with latest version of the QRD template (v. 8.0, rev.1).The variation also includes changes to sections 4.6 and4.8oftheSmPCwhich arebasedonthe recommendationsin theSmPCGuideline.TheSmPChas alsobeenmodified inorder toalign it with theupdates alreadyimplementedforNovoMixandLevemirinrelation totherenewalEMEAH/C/308/R/60andextension EMEA/H/C/528/X/44applicationsrespectively. Nofull user consultationwith targetpatientgroups on the package leaflet has been performed on the basis of a bridging report making reference to NovoMix and Levemir. The bridging report submitted by the applicant has been found acceptable. |
| IAIN/0090 | B.II.b.1.a -Replacement or addition of a manufacturing sitefor the Fp-Secondary packaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/01/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|         | site                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |           |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| IG/0137 | B.I.b.2.a-Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changesto anapprovedtestprocedure                                                                                                                                                                                                                                                                                                                                                 | 16/12/2011 | n/a        |                        |           |
| IA/0088 | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                  | 11/11/2011 | n/a        |                        |           |
|         | Thiswasanapplicationforagroupofvariations. B.I.a.1.f-Change in themanufacturer ofASor of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takes place A.7-Administrativechange-Deletion of manufacturingsites                                                                                                                                               | 28/10/2011 | n/a        |                        | IB/0087/G |
|         | This was an application for a group of variations. Additionof adevicewhichis anintegratedpartof theprimarypackaging of thefinishedproduct. B.IV.1.c-Change of a measuring or administration device-Addition orreplacement of adevicewhichis anintegratedpartoftheprimarypackaging B.1I.e.5.a.1 - Change in pack size of the finished product-Change in the number of units(e.g. tablets,ampoules,etc.）in a pack-Change within therange of the currently approvedpack sizes | 14/04/2011 | 11/07/2011 | SmPC, Labelling and PL | I1/0085/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.II.e.5.a.1-Changeinpacksizeofthefinished product - Change in the number of units (e.g. tablets,ampoules,etc.）in a pack-Change within therangeofthecurrentlyapprovedpacksizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets,ampoules,etc.）in a pack-Change within the range of the currently approved pack sizes B.II.e.5.a.1-Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules,etc.) in a pack-Change within therangeofthecurrentlyapprovedpacksizes                                                                                                                              |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0091 | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Furtherto aCHMPrequestbasedon the recommendationsfromPhvwP，theProduct Information(Summary ofProductCharacteristics section4.4andPackageLeafletsection2)isupdated by adding a warning on an increased incidence of heartfailurewhenpioglitazoneis used in combination withinsulin,especially in patients with predisposing factors. InadditiontotheabovetheMAHtookthe opportunity to update annex IIB \"Other conditions\" withthelatestwordingasperOctober2010CHMP announcmentregarding thePharmacovigilance system. This application was submitted for a group of | 17/02/2011 | 08/04/2011 | SmPC and PL | ThePhvwPwasrequestedtoconsiderwhetherthe increasedriskoffluidretentionandexacerbationofheart failure with the concomitant use ofpioglitazone and insulin should apply to all centrally authorised insulinproducts. After the review of the available evidence, during its October2010meetingthePhvwPhasconcludedthis reviewwitharecommendationto theCHMPontheneed to harmonise theSmPC andPLfor all insulinproductsby including appropriate warning. The CHMP endorsed this recommendation,andinthiscontexttheCommitteeagreed thatallcentrallyauthorisedinsulincontainingproducts should includewarningonincreasedcardiacfailurewhen pioglitazone isused incombinationwithinsulin,especially inpatientswithpredisposingfactors in thein thesection 4.4of the SmPC and section 2 of thePL. AnnexIIB\"Other conditions\"was alsoupdatedwith the latestwordingasperOctober2010CHMPannouncment regardingthePharmacovigilancesystem. |

<div style=\"page-break-after: always\"></div>

|           | worksharingprocedure according toArticle20 of CommissionRegulation(EC)No1234/2008. C.1.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,data submittedunderA45/46, or amendments toreflect aCoreSPC-Changeswith NOnewadditional data aresubmittedby theMAH                                                                                                 |            |     |                        | variations consisting ofvariationsfollowing a   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-------------------------------------------------|
| IA/0086   | B.IV.1.a.1-Changeofameasuringoradministration device-Addition orreplacement of a devicewhich is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                     | 08/04/2011 | n/a | SmPC, Labelling and PL |                                                 |
| IB/0084/G | Thiswas an applicationfor a groupof variations. A.7-Administrativechange-Deletionof manufacturing sites B.I.a.1.z-Change in the manufacturer ofASor of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.e -Change inbatch size(including batch size ranges) of AS or intermediate - The scale for a biological/immunologicalASisincreased/decreased without process change(e.g.duplication of line) | 06/12/2010 | n/a |                        |                                                 |
|           | B.I.b.2.c-Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a test procedure for a reagent, which doesnothaveasignificanteffectontheoverall                                                                                                                                                                                                                                          | 04/11/2010 | n/a |                        | IB/0082                                         |

<div style=\"page-break-after: always\"></div>

|           | quality of the AS                                                                                                                                                                                                                                                                                                                                                                            |            |            |                        |                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------|
| IA/0083/G | This was an applicationfor a group of variations. B.IV.1.a.1-Change of ameasuring or administration device - Addition or replacement of a device which is notanintegratedpartof theprimarypackaging- Device with CE marking B.IV.1.a.1-Change of a measuring oradministration device-Additionorreplacementof adevicewhichis not anintegratedpartof theprimarypackaging- Devicewith CEmarking | 03/11/2010 | 03/11/2010 | SmPC, Labelling and PL |                                                    |
| I1/0080   | To introduce changes in the manufacturing site of theactive substance. B.I.a.1.e-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS-The changerelatestoabiologicalASorastarting material [-] used in the manufacture of a biological/immunological product                                                                                                  | 23/09/2010 | 28/09/2010 |                        |                                                    |
| IA/0081   | B.IV.1.a.1-Changeofameasuringoradministration device-Additionorreplacementofadevicewhichis not anintegratedpartof theprimarypackaging- Device with CE marking                                                                                                                                                                                                                                | 01/08/2010 | n/a        | SmPC and PL            |                                                    |
| N/0079    | Minor change in labelling or package leaflet not connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                   | 04/12/2009 | n/a        | Labelling and PL       |                                                    |
| 11/0077   | Update of theSPCsection 4.4\"Specialwarnings and                                                                                                                                                                                                                                                                                                                                              | 25/06/2009 | 27/07/2009 | SmPC                   | The NovoRapid EU recent renewal application (R/72) |

<div style=\"page-break-after: always\"></div>

|         | precautions for use\" with warning about travelling and section 4.6\"Pregnancy and lactation\"with the number of exposedpregnancies toalign it with the CompanyCoreDataSheet(CCDS). UpdateofSummaryofProductCharacteristics   |            |            |                                  | obtainedpositiveCHMPopinionon20February2009. During the renewal review it was noted that the Company CoreDataSheet(CCDS)forNovoRapidhadbeenupdated with clinical trial data concerning the use during pregnancy andhypoglycaemiaprecautions.TheCHMPhas recommendedtotheMAH toupdatetheSPC accordingly. Section 4.4 was updated with warning about the use during travellingandsection4.6withthenumberofexposed pregnancies.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0078 | IA_25_b_01_Change to comply with Ph.- compliancewithEUPh.update-active substance                                                                                                                                           | 30/06/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| I1/0075 | Tochangethestatusofspecifiedproducts manufacturing sites from single product to multi productfacilities. Change(s)to the manufacturingprocessforthe finished product                                                       | 23/04/2009 | 12/05/2009 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0076 | IA_o9_Deletionofmanufacturingsite                                                                                                                                                                                          | 05/05/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| R/0072  | Renewalofthemarketing authorisation.                                                                                                                                                                                       | 19/02/2009 | 30/04/2009 | SmPC, Annex II, Labelling and PL | BasedontheCHMPreviewoftheavailableinformationand on the basis of a re-evaluation of the benefit risk balance, theCHMPisoftheopinionthatthequality,safetyand efficacyofthismedicinal productcontinues tobe adequatelyandsufficientlydemonstratedandtherefore consideredthatthebenefitriskprofileofNovoRapid continuestobefavourable.                                                                                           |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                |            |            |                        | granted with unlimited validity   |
|---------|------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| 11/0073 | Extension of the shelf-life of the drug substance. Quality changes                             | 19/02/2009 | 03/03/2009 |                        |                                   |
| IA/0074 | IA_07_a_Replacement/add.ofmanufacturingsite: Secondarypackagingsite                            | 08/01/2009 | n/a        |                        |                                   |
| IA/0071 | IA_07_a_Replacement/add.of manufacturing site: Secondary packaging site                        | 01/09/2008 | n/a        |                        |                                   |
| 11/0068 | Change(s)to themanufacturingprocessforthe activesubstance                                      | 24/07/2008 | 29/07/2008 |                        |                                   |
| II/0069 | Change to thetestprocedure and/or specification of a rawmaterial                               | 30/05/2008 | 11/06/2008 |                        |                                   |
| IA/0070 | IA_o9_Deletionofmanufacturingsite                                                              | 07/05/2008 | n/a        |                        |                                   |
| II/0065 | Change(s)to container                                                                          | 19/03/2008 | 23/04/2008 | Labelling and PL       |                                   |
| N/0063  | Minorchangeinlabellingorpackageleafletnot connected with theSPC(Art.61.3Notification)          | 17/03/2008 | n/a        | Labelling              |                                   |
| N/0062  | Minor change in labelling or package leaflet not connected with the SPC(Art.61.3 Notification) | 17/03/2008 | n/a        | PL                     |                                   |
| IA/0066 | IA_41_a_01_Change in pack size -change in no.of unitswithinrange of appr.pack size             | 25/02/2008 | 25/02/2008 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0064   | IA_28_Change in any part of primary packaging material not in contact with finished product                                                                              | 18/01/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0060   | Change(s) to the test method(s) and/or specificationsfortheactivesubstance                                                                                               | 15/11/2007   | 23/11/2007 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0061   | IA_07_a_Replacement/add.of manufacturing site: Secondarypackagingsite                                                                                                    | 10/10/2007   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1I/0059   | Qualitychanges                                                                                                                                                           | 20/09/2007   | 25/09/2007 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| I1/0058   | Inclusion of information about the use of Novorapid in elderly and patients with renal and hepatic impairment. UpdateofSummaryofProductCharacteristicsand PackageLeaflet | 19/07/2007   | 30/08/2007 | SmPC and PL | Three studies were submitted in support of the variation: -A randomised controlled,double-blind,study in subjects withtype2diabetesaged?65years -Two open-label, single dose PKstudies in non-diabetic subjectswithvaryingdegreesofhepaticimpairment and in subjects with type 1 diabetes complicated by varying degrees ofrenalimpairment,respectively. Differencesinpharmacokineticpropertiesbetweeninsulin aspart and solublehuman insulin in elderly subjects with type2diabetesweresimilar to thoseobservedinhealthy subjects and inyounger subjectswith diabetes.A decreasedabsorptionratewasobservedinelderlysubjects withtype2diabetescomparedtoyoungertype2diabetes patients and toyoungertype 1 diabetespatients. In subjectswith hepatic impairment the absorptionrate was decreased and morevariable.Data werelimited in subjectswithmoderateandsevererenalimpairment,but did not suggest any major influence of renal impairment on pharmacokineticpropertiesbetween insulin aspart. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 11/0057   | Change(s) to the manufacturing process for the activesubstance                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/05/2007   | 30/05/2007   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0056   | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16/11/2006   | 21/11/2006   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| I1/0055   | Update ofor change(s)to thepharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/11/2006   | 21/11/2006   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0052   | Thisvariationrelatestotheinclusionofinformation about usage of NovoRapid during pregnancy in the SummaryofProductCharacteristicssections4.6and 5.1,and thepackageleaflet.Furtherminorchanges weremade to theproductinformationinlinewith the latestQRDtemplates(version7)andfor harmonisationoftexts acrossthepresentations. FinallytheMAH tookthisopportunity toinclude recommendationsfor changesof theinjection sitein thepackageleaflet. UpdateofSummaryofProductCharacteristics, LabellingandPackageLeaflet | 01/06/2006   | 20/07/2006   | SmPC, Annex II, Labelling and PL | TheMAH submitted theresultof twostudies: ANA-1474was arandomised,controlled,open label, parallel-group trial comparing insulin aspart (IAsp) with human insulin (HI) in subjects with type 1 diabetes. Subjects enrolled were either already pregnant at the screeningvisitorwereplanning tobecomepregnantinthe immediatefuture. ANA-2067wasarandomised,controlled,open label, trial comparing IAsp and HI in subjects diagnosed with gestational diabetes, enrolled between gestational age 18to28weeks. ResultsfromstudyANA-1474(322exposedpregnancies: 157 to IAsp and 165 to HI) support the use of IAsp during pregnancy. The effect of IAsp, as measured by change in HbA1c, was similar to that of HI. The use of IAsp during pregnancy also seems logical considering the wide spread useinnonpregnantwomenwithtype1 diabetes and is furthersupportedby theresultof theQualityof Life assessment.Therewas alowerriskofmajor hypoglycaemia(diurnal andnocturnal)episodeswithIAsp compared toHIinANA-1474even though thedifferences |

<div style=\"page-break-after: always\"></div>

|         |                                                                                            |            |            |           | were notstatistically significant.There were no clinically significantdifferencesinpregnancyoutcomesbetweenthe treatments.No definite conclusions canbe drawnfrom the analysesofmaternalandfoetusantibodiessincethe samplesweresmall.However,theresultsdonotindicate anyimportant differencebetweeninsulin aspart andhuman insulin.Nootherunexpectedadverseadventshavebeen identified in the study. StudyANA-2067(27exposedpregnancies:14 toIAsp and 13 toHI)canonlybeseen asexploratory due tothelimited numberofsubjectsenrolled andconcernsoverthe methodologyconcerningHbAicmeasurements.   |
|---------|--------------------------------------------------------------------------------------------|------------|------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0054  | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)        | 24/05/2006 | n/a        |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| I1/0051 | Quality changes                                                                            | 27/04/2006 | 02/05/2006 |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0053 | IB_25_a_02_Change to complywithPh.- compliance with EU Ph. - excipient                     | 25/04/2006 | n/a        |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0050  | Minor change inlabelling orpackageleaflet not connected with theSPC(Art.61.3 Notification) | 21/12/2005 | n/a        | Labelling |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 11/0048 | Change(s) to the manufacturing process for the finished product                            | 17/11/2005 | 25/11/2005 |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0049 | IA_07_a_Replacement/add.ofmanufacturing site: Secondary packaging site                     | 25/10/2005 | n/a        |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IA/0047   | IA_o9_Deletionofmanufacturingsite                                                                                                                                                                                                                                            | 12/09/2005   | n/a        | Annex II and PL         |                                                                                                                                                                                                                                           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0040   | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                              | 27/07/2005   | 03/08/2005 |                         |                                                                                                                                                                                                                                           |
| IA/0046   | IA_07_a_Replacement/add.ofmanufacturingsite: Secondarypackaging site                                                                                                                                                                                                         | 12/07/2005   | n/a        |                         |                                                                                                                                                                                                                                           |
| I1/0041   | Change(s)to the manufacturingprocessforthe finished product                                                                                                                                                                                                                  | 26/05/2005   | 08/07/2005 | Annex II and PL         |                                                                                                                                                                                                                                           |
| I1/0043   | Change(s)to the testmethod(s)and/or specificationsforthe activesubstance                                                                                                                                                                                                     | 23/06/2005   | 30/06/2005 |                         |                                                                                                                                                                                                                                           |
| IA/0045   | IA_o9_Deletionofmanufacturingsite                                                                                                                                                                                                                                            | 23/05/2005   | n/a        |                         |                                                                                                                                                                                                                                           |
| N/0044    | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                          | 27/04/2005   | n/a        | Labelling               |                                                                                                                                                                                                                                           |
| I1/0034   | Change(s)to the testmethod(s)and/or specificationsfortheactivesubstance Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                                                                                          | 17/02/2005   | 30/03/2005 | SmPC,  Labelling and PL | Thisvariation concerns an update of sections 4.2, 5.1 and 5.2oftheSPCandrelevantsectionsofthePLtoinclude informationon the useof NovoRapid inchildrenwithin the agegroup2-6years.Minor amendmentshave alsobeen included in the labelling. |
| N/0042    | Changestoincludetheincreaseinthedimensionsof thePackageLeaflet,and the outerpackingmaterial, aswell astheintroductionof anoptimisedblister packing material (introduction of air cushions to protect the cartridges) in accordance with article 61 (3)ofDirective2001/83/EC. | 11/03/2005   | n/a        | PL                      |                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | Minor changeinlabelling orpackageleaflet not connected with theSPC(Art.61.3 Notification)   |            |            |                                  |                                                                                                                                                                                                                                                                                                |
|---------|---------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I/0036  | Change(s) to the manufacturing process for the finished product                             | 20/01/2005 | 27/01/2005 |                                  |                                                                                                                                                                                                                                                                                                |
| I1/0035 | Change(s)to the manufacturing processforthe finishedproduct                                 | 20/01/2005 | 27/01/2005 |                                  |                                                                                                                                                                                                                                                                                                |
| IA/0038 | IA_o5_Change in the name and/or addressof a manufacturerofthefinishedproduct                | 20/12/2004 | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                |
| IA/0037 | IA_38_a_Changeintestprocedureoffinished product-minorchangetoapprovedtestprocedure          | 20/12/2004 | n/a        |                                  |                                                                                                                                                                                                                                                                                                |
| R/0032  | Renewal of themarketing authorisation.                                                      | 29/07/2004 | 18/10/2004 | SmPC, Annex II, Labelling and PL | Basedonthereviewof the availableinformation,theCHMP wasoftheopinionthatthequality，thesafetyandthe efficacyofNovoRapidcontinuestobeadequatelyand sufficientlydemonstratedandthatthebenefit/riskprofileof NovoRapid continues to be favourable in the treatment of patientswithdiabetesmellitus. |
| I/0033  | Updateofor change(s)to thepharmaceutical documentation                                      | 16/09/2004 | 18/10/2004 | SmPC, Labelling and PL           | TheMarketingAuthorisationHolderappliedtoextendthe shelf lifeforNovorapidfrom24monthsto30months.                                                                                                                                                                                                |
| X/0027  | X-1-iii_Qualitativechangetotheactivesubstance(s)                                            | 03/06/2004 | 24/08/2004 | Annex II                         |                                                                                                                                                                                                                                                                                                |
| 11/0031 | Updateofor change(s)tothepharmaceutical documentation                                       | 22/04/2004 | 28/04/2004 |                                  |                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | TheMarketingAuthorisationHolder appliedfor an updateof section4.8of theSummaryofProduct Characteristics(SPC)and correspondent section in the Package Leaflet. In addition a class warning regarding early warning symptoms of hypoglycaemia included inSection4.4of theSPChasbeenmodified. UpdateofSummaryofProductCharacteristicsand PackageLeaflet                                                                                              | 26/02/2004   | 07/04/2004   | SmPC and PL           | II/0029               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|-----------------------|
| I1/0028 | TheMarketingAuthorisationHolder appliedfor a revisionoftheSummaryofProductCharacteristics andPackageLeaflet(PL) tostandardise the product informationtextfor all NovoNordiskA/Sinsulin products,and to reflect in the PL the results of the readabilitytestsperformedforActrapid.AnnexIIhas alsobeenincludedwithacompletelistof presentations related to each manufacturer responsibleforbatchrelease. UpdateofSummaryofProductCharacteristicsand | 26/02/2004   | 07/04/2004   | SmPC, Annex II and PL | PackageLeaflet        |
|         | Update of or change(s) to the pharmaceutical                                                                                                                                                                                                                                                                                                                                                                                                      | 24/03/2004   | 31/03/2004   |                       | I1/0030 documentation |
|         | 15_Minor changes in manufacture of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                          | 25/09/2003   | 29/09/2003   |                       | 1/0026                |
|         | 01_Changeinoradditionofmanufacturingsite(s)for part or all of the manufacturing process                                                                                                                                                                                                                                                                                                                                                           | 16/07/2003   | 22/08/2003   | Annex II and PL       | 1/0025                |

<div style=\"page-break-after: always\"></div>

| 1/0024   | 01_Change inor addition of manufacturingsite(s)for partorallofthemanufacturingprocess   | 20/06/2003   | 18/07/2003   | Annex II and PL        |                        |
|----------|-----------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------|
|          | UpdateofSummaryofProductCharacteristicsand                                              | 23/01/2003   | 06/06/2003   | SmPC, Labelling and PL | II/0022 PackageLeaflet |
| X/0019   | X-3-v_Additionofanewrouteofadministration                                               | 19/12/2002   | 04/06/2003   | SmPC, Labelling and PL |                        |
| X/0016   | X-3-v_Addition of a newroute of administration                                          | 19/12/2002   | 04/06/2003   | SmPC, Labelling and PL |                        |
| I1/0021  |                                                                                         | 18/12/2002   | 04/06/2003   | SmPC, Labelling and PL | Newpresentation(s)     |
| 11/0013  | UpdateofSummaryofProductCharacteristicsand                                              | 21/03/2002   | 15/07/2002   | SmPC, Labelling and PL | Package Leaflet        |
| 1/0018   | 15_Minor changes inmanufacture of themedicinal                                          | 27/06/2002   | 10/07/2002   |                        | product                |
|          | 16_Change in thebatch size of finishedproduct                                           | 30/05/2002   | 10/06/2002   |                        | 1/0017                 |
|          | 30_Change inpack sizefor a medicinal product                                            | 16/01/2002   | 02/04/2002   | SmPC, Labelling and PL | 1/0015                 |
| II/0012  | Change(s)to the testmethod(s)and/or                                                     | 21/02/2002   | 26/02/2002   |                        |                        |

<div style=\"page-break-after: always\"></div>

|          | specificationsfor the active substance                                                 |            |            |                         |         |
|----------|----------------------------------------------------------------------------------------|------------|------------|-------------------------|---------|
|          | 12_Minorchangeof manufacturingprocessof the activesubstance                            | 21/02/2002 | 26/02/2002 |                         | 1/0014  |
| 1/0011   | 16_Change in thebatchsizeoffinishedproduct                                             | 13/12/2001 | 07/01/2002 |                         |         |
|          | Quality changes                                                                        | 20/09/2001 | 22/10/2001 |                         | I1/0010 |
|          | Quality changes                                                                        | 26/04/2001 | 26/07/2001 | SmPC and PL             | I1/0008 |
| 1I1/0007 | UpdateofSummaryofProductCharacteristicsand Package Leaflet                             | 14/12/2000 | 23/04/2001 | SmPC and PL             |         |
| 1/0009   | 24_Changein testprocedure of activesubstance 25_Changein testproceduresof themedicinal | 01/03/2001 | 02/04/2001 |                         | product |
| 11/0006  | Update of Summary of Product Characteristics and PackageLeaflet                        | 28/08/2000 | 15/01/2001 | SmPC, Labelling and PL  |         |
| II/0005  | UpdateofSummaryofProductCharacteristicsand PackageLeaflet                              | 18/11/1999 | 13/04/2000 | SmPC,  Labelling and PL |         |
| I1/0004  | New presentation(s)                                                                    | 21/10/1999 | 08/02/2000 | SmPC, Labelling and PL  |         |
| I1/0003  | New presentation(s)                                                                    | 21/10/1999 | 08/02/2000 | SmPC, Labelling and     |         |

<div style=\"page-break-after: always\"></div>

|                                              |            |            | PL                     |                         |
|----------------------------------------------|------------|------------|------------------------|-------------------------|
| Newpresentation(s)                           | 21/10/1999 | 08/02/2000 | SmPC, Labelling and PL | I1/0002                 |
| 12_Minor change ofmanufacturingprocessof the | 18/11/1999 | 15/12/1999 |                        | 1/0001 active substance |